Head-to-head evidence
LNK01001 vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1 · full Atopic Dermatitis pipeline
LNK01001
Developed by Lynk Pharmaceuticals
NCT06277245 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 356 patients that measured EASI-75 skin clearance and Investigator's Global Assessment response at week 16, the standard efficacy measures for atopic dermatitis. Both the 12 mg and 24 mg doses produced large, statistically significant improvements over placebo on both endpoints.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03607422 · Phase 3 · completed
Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).
Next expected readout: January 2027 · NCT06701331 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LNK01001's landscape · upadacitinib's landscape